Physician profile
Stephen Taylor
NPI 1447354907
$5,945.59
in general payments reported to CMS, 2019-2025
11 companies · $5,521 in 2025
The $5,521 reported for 2025 was more than what 92% of Addiction Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $152).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $425 · 2025: $5,521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,560 · Travel and Lodging: $1,449 · Food and Beverage: $937.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,560.00 |
| Travel and Lodging | $1,448.50 |
| Food and Beverage | $937.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emergent Biosolutions INC. | $5,109.91 | 2025 | |
| Indivior INC. | $201.96 | 2024-2025 | Sublocade |
| Neuronetics, INC. | $114.35 | 2024 | Neurostar Tms Therapy System |
| Alkermes, INC. | $110.46 | 2024-2025 | Vivitrol |
| Braeburn INC. | $107.97 | 2024-2025 | Brixadi |
| Janssen Pharmaceuticals, INC | $91.46 | 2024-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.45 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $42.18 | 2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $31.36 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $29.78 | 2025 | Auvelity |
| Orexo US, INC. | $14.71 | 2024 | Zubsolv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.